News from the healthcare data industry
DURHAM, N.C., Aug. 21, 2024 /PRNewswire/ — Real-world evidence (RWE) leader, Target RWE, today announced its new patient-centric platform engage™ – utilized by both patients and study sites to seamlessly capture digital,...
The company announced its suite of analytical products, named Syndicated Science™ Insights, which includes interactive, robust analyses across a suite of therapeutic areas DURHAM, N.C., Aug. 23, 2023 /PRNewswire/ — Real-world evidence (RWE)...
Company Additionally Announces Exclusive Biorepository Milestoneof 10,000+ TARGET-DERM Samples DURHAM, N.C., Jan. 11, 2023 /PRNewswire/ — Target RWE, the leader and largest provider of real-world evidence (RWE) in non-cancer conditions, announced today the launch...
DURHAM, N.C., Oct. 18, 2022 /PRNewswire/ — Today, real world evidence (RWE) leader Target RWE announced a partnership with the American Association for the Study of Liver Diseases (AASLD) to support its Cirrhosis Quality Collaborative (CQC),...
DURHAM, N.C., Aug. 25, 2022 /PRNewswire/ — Target RWE will present a range of methodological and applied research at the 2022 International Society for Pharmacoepidemiology’s annual conference (ICPE) in Copenhagen. Target RWE scientists will deliver...
DURHAM, N.C., Aug. 24, 2022 /PRNewswire/ — Real-world evidence leader Target RWE announced its latest acquisition of the curation team (legacy Real World Data team) from Ciox Health which will expand the company’s real...
DURHAM, N.C., Aug. 23, 2022 /PRNewswire/ — Target RWE, a leading real-world evidence (RWE) company, will unveil its fully integrated new brand and Syndicated Science™ analytical solution while attending the 2022 International Society...
DURHAM, N.C., July 20, 2022 /PRNewswire/ — New data from Target RWE‘s TARGET-PBC cohort found that pruritis (itching) was reported in 81% of patients with Primary Biliary Cholangitis (PBC), with those reporting clinically...
DURHAM, N.C., July 20, 2022 /PRNewswire/ — New data from Target RWE‘s TARGET-PBC cohort found that pruritis (itching) was reported in 81% of patients with Primary Biliary Cholangitis (PBC), with those reporting clinically...
DURHAM, N.C., May 22, 2022 /PRNewswire/ — New data shows that more than a third (36.6%) of ulcerative colitis (UC) patients who have previously responded to advanced therapies experienced a loss of...